Abstract
Osteoarthritis (OA) has traditionally been viewed as a non-inflammatory arthropathy and has not been considered a ‘serious disease’. However, this view has radically changed in recent years, due to the complexity and heterogeneity of the patient populations, spiralling socio-economical costs and long-term impact on the quality of life of affected individuals. There is an acute need for objective and non-invasive diagnostic biomarkers in OA, markers that can stratify patient subtypes and thereby direct therapeutic treatments at an earlier disease stage (read personal health care (PHC)) (Conaghan, 2013). Increased interest in the development of new diagnostic and prognostic tests for early forms of OA may incorporate the use of blood-based biomarkers; however, both research and regulated development and approval are still needed to reach a diagnostically important significant point where a given biomarker will benefit the clinical management of the patient.